Advertisement

Topics

Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors

09:30 EST 12 Dec 2017 | GlobalNewsWire (2014)

Kalamazoo, Michigan - December 12, 2017 - Stryker Corporation (NYSE:SYK) announced today that after 44 years of distinguished service, Mr. Howard E. Cox, Jr. has notified the Company that he will not stand for re-election at Stryker's 2018 Annual Meeting of Shareholders, which is expected to be held on May 2, 2018.  In light of Mr. Cox's immense contributions to the Company since before it was a publicly traded company to its current position as a leading global medical technology firm, he will be named Director Emeritus. 

Mr. Cox has held various leadership positions with Greylock and its affiliated venture capital partnerships since 1971 and is currently a Special Limited Partner. He is also currently a Director, Secretary of Defense Business Board, and a member of the Harvard Medical School Board of Fellows and the Investment Committees of the Dana Farber Cancer Institute and the Boston Museum of Fine Arts.  His broad and deep experience as a board member and extensive experience in venture capital have enabled the valuable contributions he has made to Stryker's Board since 1974, especially as it relates to the assessment of potential acquisitions.

"We sincerely appreciate Howard's unwavering dedication to our Board," said Kevin A. Lobo, Chairman and Chief Executive Officer. "We thank Howard for serving on our Board for over four decades, and for being a champion of our growth ambitions and consistent success. We wish him all the best and thank him for his guidance in helping Stryker deliver on its mission."

Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact:
Yin Becker, Stryker Corporation, 269-385-2600 or yin.becker@stryker.com





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Stryker Corporation via Globenewswire

NEXT ARTICLE

More From BioPortfolio on "Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors "

Quick Search
Advertisement
 

Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...